🔎 Trials Near Me

ホーム › クローン病 › テキサス › San Antonio

San Antonio、TXにおけるクローン病の臨床試験

San Antonioとその周辺地域(約30マイル以内)の拠点で、クローン病に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト(英語)

ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

被験者募集中第2相
  • Southern Star Research Institute /ID# 280822, San Antonio
18歳〜75歳 · 全性別 · 2026/10/05更新 · NCT07697456

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

被験者募集中第3相
  • Southern Star Research Institute ( Site 0299), San Antonio
全年齢 · 全性別 · 2026/10/02更新 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

被験者募集中第3相
  • Southern Star Research Institute ( Site 5000), San Antonio
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

被験者募集中第2相
  • Sun Research Institute /ID# 266723, San Antonio
  • Southern Star Research Institute /ID# 278124, San Antonio
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

被験者募集中第2相
  • Southern Star Research Institute, LLC, San Antonio
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

被験者募集中第3相
  • Gastroenterology Research of America, LLC, San Antonio
  • Southern Star Research Institute, LLC, San Antonio
18歳以上 · 全性別 · 2026/09/25更新 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

被験者募集中第2/3相
  • Southern Star Research Institute, LLC, San Antonio
18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

被験者募集中第3相
  • Gastroenterology Research of San Antonio, San Antonio
  • Southern Star Research Institute, San Antonio
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

被験者募集中第3相
  • Gastroenterology Research of San Antonio LLC-Site Number: 8400054, San Antonio
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

被験者募集中第3相
  • Gastroenterology Research of San Antonio LLC-Site Number: 8400054, San Antonio
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184944

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

被験者募集中第2相
  • Southern Star Research Institute, San Antonio
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07483099

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

被験者募集中第2相
  • Southern Star Research Institute, San Antonio
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07483073

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

被験者募集中第4相
  • Gastroenterology Research of San Antonio, LLC, San Antonio
  • Southern Star Research Institute, LLC., San Antonio
18歳〜70歳 · 全性別 · 2026/09/09更新 · NCT06045754

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

被験者募集中第3相
  • Southern Star Research Institute, LLC, San Antonio
18歳〜65歳 · 全性別 · 2026/05/27更新 · NCT06227910

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

被験者募集中第2相
  • Southern Star Research Institute, LLC, San Antonio
18歳〜75歳 · 全性別 · 2026/04/27更新 · NCT06456593

他の都市におけるクローン病の試験

San Antonioにおける他の研究

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。